The Anti-HIV Effects of Saquinavir Soft Gelatin Capsules Versus Indinavir in Patients Who Have Used Saquinavir Hard Gelatin Capsules for One Year
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00000848 |
|
Recruitment Status :
Completed
First Posted : August 31, 2001
Last Update Posted : November 4, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
To determine, in HIV-infected patients, whether switching to a new soft gelatin capsule formulation of saquinavir or to indinavir following prolonged use of the original hard capsule formulation of saquinavir results in an acute decrease in plasma HIV RNA.
Resistance to anti-HIV agents occurs with increasing duration of use. In vitro studies have shown that cross-resistance occurs among protease inhibitors, although no clinical trials have been conducted to examine antiretroviral activity with sequential use of protease inhibitors or to determine whether saquinavir resistance can be overcome with higher concentrations of the drug.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Infections | Drug: Indinavir sulfate Drug: Saquinavir | Phase 2 |
Resistance to anti-HIV agents occurs with increasing duration of use. In vitro studies have shown that cross-resistance occurs among protease inhibitors, although no clinical trials have been conducted to examine antiretroviral activity with sequential use of protease inhibitors or to determine whether saquinavir resistance can be overcome with higher concentrations of the drug.
Patients who are currently receiving hard capsule saquinavir are randomized to continue receiving hard capsule saquinavir or to switch to soft gelatin capsule saquinavir or indinavir. At week 8, patients receiving the hard capsule formulation will switch to open-label indinavir for weeks 8-24. Patients on the other two arms will remain on their assigned regimen for the entire 24 weeks unless they have no virologic response by week 8, in which case they will be crossed-over to open-label therapy with the alternative drug (i.e., either soft gelatin capsule saquinavir or indinavir).
AS PER AMENDMENT 12/23/96: Viral RNA from weeks 16 and 24 will be assayed in batch after week 24. Patients who exhibit an antiviral response based on this assay will be allowed to continue their current drug assignment for a total of 12 months.
AS PER AMENDMENT 5/7/97: Based on an interim analysis performed after 72 patients had completed 8 weeks of therapy, the study was closed as of March 7, 1997. Patients currently enrolled may stop their participation in the trial and seek other anti-retroviral therapies or may continue on study. Patients on hard capsule saquinavir who remain on study will be switched to indinavir at 8 weeks. Patients on soft gel capsule saquinavir may switch immediately to indinavir or, when results of HIV RNA and CD4 cell counts are available, may choose to switch to indinavir or remain on soft gel capsule saquinavir. Patients receiving indinavir will continue that agent. Follow-up for all patients will end on 7/4/97.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 144 participants |
| Primary Purpose: | Treatment |
| Official Title: | The Antiviral Effect of Switching From Hard Capsule Saquinavir (SQVhc) to the Soft Gelatin Capsule of Saquinavir (SQVsc) Versus Switching to Indinavir (IDV) After 1 Year of Saquinavir Use |
| Actual Study Completion Date : | October 1998 |
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Required:
- PCP prophylaxis if CD4 count <= 200 cells/mm3.
Allowed:
- Intralesional therapy for KS.
- Vitamins.
- Nucleoside RT inhibitors, provided regimen remains stable for first 8 weeks of study.
Concurrent Treatment:
Allowed:
- Acupuncture.
- Visualization techniques.
Patients must have:
- HIV infection.
- Prior hard capsule saquinavir at 1800 mg/day for more than 1 year.
Prior Medication:
Allowed:
- Prior saquinavir.
- Prior antiretrovirals, excluding protease inhibitors other than saquinavir.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Psychological condition or medical instability that would interfere with study evaluation or procedures.
AS PER AMENDMENT 5/7/97:
- Active tuberculosis.
Concurrent Medication:
Excluded:
- Protease inhibitors other than study drugs.
- Non-nucleoside RT inhibitors.
- Interferon.
- Interleukins.
- GM-CSF.
- HIV vaccines.
- Systemic cytotoxic chemotherapy.
- Investigational drugs other than study medications.
- Rifabutin.
- Rifampin.
- Midazolam.
- Triazolam.
- Ketoconazole.
- Delavirdine.
- Cisapride.
- Terfenadine.
- Astemizole.
AS PER AMENDMENT 5/7/97:
- Nevirapine.
Patients with the following prior conditions are excluded:
- Unexplained fever > 38.5 C for any 7 days within 30 days prior to study entry.
- Diarrhea persisting for 15 days within 30 days prior to study entry.
Prior Medication:
Excluded:
- Any prior protease inhibitor other than saquinavir.
Excluded within the past 2 months.
- Change in antiretroviral regimen.
- Systemic chemotherapy for KS.
Excluded within the past month:
- Non-nucleoside RT inhibitors.
- Interferons.
- Interleukins.
- HIV vaccines.
- Experimental therapies.
Excluded within the past 2 weeks:
- Rifabutin.
- Cisapride.
- Terfenadine.
- Astemizole.
- Midazolam.
- Triazolam.
- Oral ketoconazole.
- Delavirdine.
- Acute therapy for infection or other medical illness.
Active substance abuse that would interfere with study evaluation or procedures.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000848
| United States, California | |
| Stanford CRS | |
| Palo Alto, California, United States, 94304 | |
| Ucsf Aids Crs | |
| San Francisco, California, United States, 94110 | |
| Harbor-UCLA Med. Ctr. CRS | |
| Torrance, California, United States, 90502 | |
| United States, Colorado | |
| University of Colorado Hospital CRS | |
| Aurora, Colorado, United States, 80045 | |
| United States, Florida | |
| Univ. of Miami AIDS CRS | |
| Miami, Florida, United States, 33136 | |
| United States, Illinois | |
| Northwestern University CRS | |
| Chicago, Illinois, United States, 60611 | |
| Rush Univ. Med. Ctr. ACTG CRS | |
| Chicago, Illinois, United States, 60612 | |
| United States, Massachusetts | |
| Massachusetts General Hospital ACTG CRS | |
| Boston, Massachusetts, United States, 02114 | |
| United States, Missouri | |
| Washington U CRS | |
| Saint Louis, Missouri, United States, 63110 | |
| St. Louis ConnectCare, Infectious Diseases Clinic | |
| Saint Louis, Missouri, United States, 63112 | |
| United States, New York | |
| SUNY - Buffalo, Erie County Medical Ctr. | |
| Buffalo, New York, United States, 14260 | |
| Beth Israel Med. Ctr. (Mt. Sinai) | |
| New York, New York, United States, 10003 | |
| NY Univ. HIV/AIDS CRS | |
| New York, New York, United States, 10016 | |
| Univ. of Rochester ACTG CRS | |
| Rochester, New York, United States, 14642 | |
| United States, Ohio | |
| The Ohio State Univ. AIDS CRS | |
| Columbus, Ohio, United States, 43210 | |
| United States, Washington | |
| University of Washington AIDS CRS | |
| Seattle, Washington, United States, 98104 | |
| Study Chair: | Para MF | ||
| Study Chair: | Collier A | ||
| Study Chair: | Coombs R |
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00000848 |
| Other Study ID Numbers: |
ACTG 333 11305 ( Registry Identifier: DAIDS ES ) |
| First Posted: | August 31, 2001 Key Record Dates |
| Last Update Posted: | November 4, 2021 |
| Last Verified: | October 2021 |
|
Administration, Oral Acquired Immunodeficiency Syndrome AIDS-Related Complex Antiviral Agents HIV Protease Inhibitors |
Biological Markers Indinavir Viremia RNA, Viral Saquinavir |
|
HIV Infections Blood-Borne Infections Communicable Diseases Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Immunologic Deficiency Syndromes Immune System Diseases Indinavir |
Saquinavir HIV Protease Inhibitors Viral Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors |